One Touch VerioIQ US Clinical Outcomes Study

Not Applicable

Terminated

• Conditions: Diabetes
• Interventions: Device: One Touch VerioIQ Blood Glucose Monitor

• Registration Number: NCT01627899
• Lead Sponsor: LifeScan

Brief Summary

Evaluation of the clinical benefits of One Touch VerioIQ system

Detailed Description

Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.

Study Timeline

• Study First Submitted: 2012-06-22
• Study First Submitted QC: 2012-06-22
• Study First Posted: 2012-06-26
• Study Start: 2012-10-01
• Primary Completion: 2013-05-01
• Study Completion: 2013-07-01
• Results First Submitted: 2018-02-26
• Status Verified: 2018-07
• Results First Submitted QC: 2018-07-06
• Last Update Submitted: 2018-07-06
• Results First Posted: 2018-08-02
• Last Update Posted: 2018-08-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• male or female at least 18 to 80 years old
• ADA guidelines for FPG and PPG appropriate
• A1C greater or equal to 8.0% and less than or equal to 10.5%
• lab A1C greater than or equal to 8.0% in the last 6-12mths
• Diagnosed with type 1 or 2 in at least last 1 year
• on stable dose of OADs for at least 3mths prior to screening
• willingness to test 7 BGM tests per day
• willing to remain on same therapy as baseline (MDI) for duration of study

Exclusion Criteria

• unlikely to be compliant to study procedures
• has or has currently used One Touch VerioIQ
• Is on fixed doses of insulin for MDI therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
VerioIQ	One Touch VerioIQ Blood Glucose Monitor	Subjects replaced own Blood Glucose Monitoring system with VerioIQ.

Primary Outcome Measures

Name	Time	Method
Change in A1C From Baseline to Week 24	24 weeks	Change in A1C from baseline to week 24

Secondary Outcome Measures

Name	Time	Method
Change in FPG From Baseline to 24 Weeks and Over Time	24 weeks and over time	Change in Fasting Plasma Glucose (FPG) from baseline to 24 weeks and over time
Change in Proportion of Subjects With A1C Less Than or Equal to 7.0% at Week 24	24 weeks
Change in A1C From Baseline to Week 12	12 weeks	Change in A1C from baseline to week 12
Change in 30 Day Mean Glucose Comparing First Month to Last Month After 24 Weeks	24 weeks